Real-World Analysis of Potential Pharmacokinetic and Pharmacodynamic Drug Interactions with Apixaban in Patients with Non-Valvular Atrial Fibrillation

References

• Morillo CA, Banerjee A, Perel P, Wood D, Jouven X. Atrial fibrillation: the current epidemic. J Geriatr Cardiol. 2017;14(3):195–203. doi:10.11909/j.issn.1671-5411.2017.03.01128592963
   PubMedGoogle Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart rhythm society. J Am Coll Cardiol. 2019;74(1):104–132. doi:10.1016/j.jacc.2019.01.01130703431
   PubMed Web of Science ®Google Scholar
• Vranckx P, Valgimigli M, Heidbuchel H. The significance of drug-drug and drug-food interactions of oral anticoagulation. Arrhythm Electrophysiol Rev. 2018;7(1):55–61. doi:10.15420/aer.2017.50.129636974
   PubMed Web of Science ®Google Scholar
• Roberts AG, Gibbs ME. Mechanisms and the clinical relevance of complex drug-drug interactions. Clin Pharmacol. 2018;10:123–134. doi:10.2147/CPAA.S14611530310332
   PubMed Web of Science ®Google Scholar
• Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A. Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):15–31. doi:10.1007/s11239-015-1314-326780737
   PubMed Web of Science ®Google Scholar
• Bernier M, Lancrerot SL, Rocher F, et al. Major bleeding events in octagenarians associated with drug interactions between dabigatran and P-gp inhibitors. J Geriatr Cardiol. 2019;16(11):806–811.31853245
   PubMedGoogle Scholar
• Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013;127(5):634–640. doi:10.1161/CIRCULATIONAHA.112.11538623271794
   PubMed Web of Science ®Google Scholar
• Jaspers Focks J, Brouwer MA, Wojdyla DM, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016;353:i2868. doi:10.1136/bmj.i286827306620
   PubMed Web of Science ®Google Scholar
• Rose DK, Bar B. Direct oral anticoagulant agents: pharmacologic profile, indications, coagulation monitoring, and reversal agents. J Stroke Cerebrovasc Dis. 2018;27(8):2049–2058. doi:10.1016/j.jstrokecerebrovasdis.2018.04.00429753603
   PubMed Web of Science ®Google Scholar
• Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119–2126. doi:10.1111/jth.1314026764429
   PubMed Web of Science ®Google Scholar
• Hirsh Raccah B, Rottenstreich A, Zacks N, et al. Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients. J Thromb Thrombolysis. 2018;46(4):521–527. doi:10.1007/s11239-018-1738-730196343
   PubMed Web of Science ®Google Scholar
• Forbes HL, Polasek TM. Potential drug-drug interactions with direct oral anticoagulants in elderly hospitalized patients. Ther Adv Drug Saf. 2017;8(10):319–328. doi:10.1177/204209861771981529593860
   PubMed Web of Science ®Google Scholar
• Chin PK, Vella-Brincat JW, Walker SL, Barclay ML, Begg EJ. Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital. Intern Med J. 2013;43(7):778–783. doi:10.1111/imj.1217023611064
   PubMed Web of Science ®Google Scholar
• Armbruster AL, Buehler KS, Min SH, Riley M, Daly MW. Evaluation of dabigatran for appropriateness of use and bleeding events in a community hospital setting. Am Health Drug Benefits. 2014;7(7):376–384.25525494
   PubMedGoogle Scholar
• Sidman E, Probst LA, Darko W, Miller CD. Evaluation of dabigatran utilization and risk among hospitalized patients. Ann Pharmacother. 2014;48(3):349–353. doi:10.1177/106002801351372224259660
   PubMed Web of Science ®Google Scholar
• Proietti M, Raparelli V, Olshansky B, Lip GYH. Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. Clin Res Cardiol. 2016;105(5):412–420. doi:10.1007/s00392-015-0936-y26525391
   PubMed Web of Science ®Google Scholar
• Kreutz R, Haas S, Holberg G, et al. Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactions. Br J Clin Pharmacol. 2016;81(4):724–734. doi:10.1111/bcp.1283626580706
   PubMed Web of Science ®Google Scholar
• Quinn GR, Singer DE, Chang Y, et al. Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. Am J Cardiol. 2014;114(4):583–586. doi:10.1016/j.amjcard.2014.05.03725001151
   PubMed Web of Science ®Google Scholar
• Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging Dis. 2018;9(1):143–150. doi:10.14336/AD.2017.030629392089
   PubMed Web of Science ®Google Scholar
• Gargiulo G, Goette A, Tijssen J, et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J. 2019;40(46):3757–3767. doi:10.1093/eurheartj/ehz73231651946
   PubMed Web of Science ®Google Scholar
• Shammas FV, Dickstein K. Clinical pharmacokinetics in heart failure. An updated review. Clin Pharmacokinet. 1988;15(2):94–113. doi:10.2165/00003088-198815020-000023064953
   PubMed Web of Science ®Google Scholar
• Mastromarino V, Casenghi M, Testa M, et al. Polypharmacy in heart failure patients. Curr Heart Fail Rep. 2014;11(2):212–219. doi:10.1007/s11897-014-0186-824493574
   PubMedGoogle Scholar
• Admassie E, Melese T, Mequanent W, Hailu W, Srikanth BA. Extent of poly-pharmacy, occurrence and associated factors of drug-drug interaction and potential adverse drug reactions in Gondar Teaching Referral Hospital, North West Ethiopia. J Adv Pharm Technol Res. 2013;4(4):183–189. doi:10.4103/2231-4040.12141224350048
   PubMedGoogle Scholar
• Palleria C, Di Paolo A, Giofre C, et al. Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci. 2013;18(7):601–610.24516494
   PubMed Web of Science ®Google Scholar